Apisarnthanarax N - Search Results

1

Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.

Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Duvic M, et al. Among authors: apisarnthanarax n. J Am Acad Dermatol. 2003 Jul;49(1):35-49. doi: 10.1067/mjd.2003.449. J Am Acad Dermatol. 2003. PMID: 12833006

2

Treatment of cutaneous T cell lymphoma: current status and future directions.

Apisarnthanarax N, Talpur R, Duvic M. Apisarnthanarax N, et al. Am J Clin Dermatol. 2002;3(3):193-215. doi: 10.2165/00128071-200203030-00006. Am J Clin Dermatol. 2002. PMID: 11978140 Review.

3

Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Talpur R, et al. Among authors: apisarnthanarax n. J Am Acad Dermatol. 2002 Nov;47(5):672-84. doi: 10.1067/mjd.2002.124607. J Am Acad Dermatol. 2002. PMID: 12399758

4

Mycosis fungoides with follicular mucinosis displaying aggressive tumor-stage transformation : successful treatment using radiation therapy plus oral bexarotene combination therapy.

Apisarnthanarax N, Ha CS, Duvic M. Apisarnthanarax N, et al. Am J Clin Dermatol. 2003;4(6):429-33. doi: 10.2165/00128071-200304060-00006. Am J Clin Dermatol. 2003. PMID: 12762834

5

Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.

Apisarnthanarax N, Talpur R, Ward S, Ni X, Kim HW, Duvic M. Apisarnthanarax N, et al. J Am Acad Dermatol. 2004 Apr;50(4):600-7. doi: 10.1016/j.jaad.2003.09.005. J Am Acad Dermatol. 2004. PMID: 15034511 Clinical Trial.

6

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M. Talpur R, et al. Among authors: apisarnthanarax n. J Invest Dermatol. 2006 Mar;126(3):575-83. doi: 10.1038/sj.jid.5700122. J Invest Dermatol. 2006. PMID: 16410787 Free article.

7

Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.

Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Duvic M, et al. Among authors: apisarnthanarax n. Clin Lymphoma Myeloma. 2006 Jul;7(1):51-8. doi: 10.3816/CLM.2006.n.039. Clin Lymphoma Myeloma. 2006. PMID: 16879770 Clinical Trial.

8

Cutaneous T-cell lymphoma. New immunomodulators.

Apisarnthanarax N, Duvic M. Apisarnthanarax N, et al. Dermatol Clin. 2001 Oct;19(4):737-48. doi: 10.1016/s0733-8635(05)70312-0. Dermatol Clin. 2001. PMID: 11705358 Review.

9

Therapy options in cutaneous T-cell lymphoma.

Apisarnthanarax N, Duvic M. Apisarnthanarax N, et al. Expert Rev Anticancer Ther. 2001 Oct;1(3):403-20. doi: 10.1586/14737140.1.3.403. Expert Rev Anticancer Ther. 2001. PMID: 12113107 Review.

10

Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).

Talpur R, Apisarnthanarax N, Ward S, Duvic M. Talpur R, et al. Among authors: apisarnthanarax n. Leuk Lymphoma. 2002 Jan;43(1):121-6. doi: 10.1080/10428190210183. Leuk Lymphoma. 2002. PMID: 11908715

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

16 results

Search Page